BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Han All Pharmaceutical Co., Ltd. (009420.KS) And Yuhan Corporation Complete License Agreement For A Unique Cardiovascular Combination Product For The Korean Market


6/4/2009 12:56:43 PM

On May 28, 2009, Yuhan Pharma agreed to in-license HanAll Pharmaceutical’s HL 040, a unique and proprietary time-delayed release formulation combining atorvastatin Ca (immediate release) and losartan potassium (delayed release). Yuhan obtains exclusive rights to co-develop and commercialize HL 040 for the Korean territory. This is the first out-licensing of HanAll’s unique XC Hybrid Combination Cardiovascular pipeline of products. Terms were not disclosed.

About HanAll Pharmaceuticals and XC Hybrid Combination Cardiovascular products: The Company has developed over 30 different combinations of cardiovascular products through its innovative and proprietary XC Hybrid Combination formulation technology. XC Hybrid Combination formulation provides the efficacy, safety and lack of drug-drug interaction of monotherapy BUT also provides the benefits of cardiovascular combination drugs desired by patients and prescribers. The unique formulation avoids the drug-drug interaction at the cytochrome P-450 isoenzyme, CYP3A4, and also P-glycoprotein transporter interactions. This is achieved by the unique time separation and delayed release PK profile of the combination products. These drug-drug interactions with co-administration or conventional combination products (simultaneous release profile) could prove to be serious in older patients and patients with mild to severe renal dysfunction.

HanAll will begin Phase Ib/II clinical studies in the U.S. and Korea in Q3 2009 with its lead product, HL 007, a double matrix combination formulation of simvastatin (immediate release) and amlodipine (delayed release). Bioequivalency and drug interaction studies will be carried out. A second U.S. clinical trial is scheduled for later this year to confirm the time-delayed release product profile of HanAll’s second lead product, HL 008, a combination of losartan and amlodipine.

In addition, HanAll also conducts R&D in the promising areas of oral biologics, anti-atopic dermatitis and second generation metformin products. The company seeks global or regional partners to commercialize these innovative programs.

About Yuhan Corporation

Yuhan is one of the largest pharmaceutical companies in Korea with sales of $500 million USD in 2008. With over 82 years of history, Yuhan founded joint ventures with worldwide pharmaceutical companies (Yuhan-SmithKline, Yuhan-SP, and Yuhan-Cyanamid Co., Ltd.) in Korea. The company is developing and commercializing many leading drugs in the areas of cardiovascular/metabolic, respiratory, anti-infectives, rheumatology and gastrointestinal disorders. The company currently markets the generic versions of atorvastatin and losartan. In addition, Yuhan exported YH1885 (anti-ulcer substance) technologies to SmithKline Beecham Corp. in 2000 and commercialized Revanex (Revaprazan: anti-ulcer substance) in 2008.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES